Wolters Kluwer acquires Open Access publisher;
Expands Breadth of Lippincott Journal Portfolio
Waltham, MA, September 30, 2022 – Wolters Kluwer Health announced today that it has signed and completed an agreement to acquire IJS Publishing Group (IJSPG), a UK-based provider of peer-reviewed medical journals supporting scientists and authors. The IJSPG portfolio consists of 10 journal titles, including the International Journal of Surgery (IJS), IJS Case Reports (IJSCR), and Annals of Medicine and Surgery (AMS).
IJSPG will become part of Health Learning, Research & Practice (LRP), which offers the Ovid® medical research solution, publishes over 300 medical journals and hundreds of medical and nursing books, and produces digital nursing solutions for education and practice. The acquisition expands the breadth and depth of the Lippincott journal portfolio with high impact factor, surgery-related research and strengthens its Open Access position with several well-established journals accessible in over a dozen international databases and platforms.
Vikram Savkar, Senior Vice President and General Manager of the Health LRP Medicine Segment at Wolters Kluwer, stated: “Enabling contributors, clinicians, and researchers to benefit globally from research as supported by IJS Publishing Group reinforces our commitment to peer review and Open Access to deliver the best evidence for decision-making. We are committed to delivering trusted content that is discoverable and accessible to advance science and the best care everywhere.”
“For nearly 20 years, IJS Publishing Group has developed innovative and best-in-class products and services across multiple market segments. We are excited by Wolters Kluwer’s leadership in technology-driven research publishing. Its track record of results growing its Lippincott journal portfolio make it a good fit for our next phase of growth for IJSPG,” commented Dr. Riaz Agha, IJSPG Founder, CEO and Chairman and Maliha Agha, IJSPG Director.
In 2021, IJS Publishing Group generated approximately $2 million in gross revenues. Wolters Kluwer expects the investment to deliver a return on invested capital (ROIC) above its weighted cost of capital (8%) within 3-5 years and expects the transaction to have an immaterial impact on adjusted earnings.
###
About Wolters Kluwer
Wolters Kluwer (Euronext: WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,800 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer Health provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
| Media | Investors/Analysts | |
| Gerbert van Genderen Stort | André Rebelo | Meg Geldens |
| Corporate Communications | Wolters Kluwer Health | Investor Relations |
| t + 31 172 641 230 | t +1 781 392 2411 | t + 31 172 641 407 |
| press@wolterskluwer.com | andre.rebelo@wolterskluwer.com | ir@wolterskluwer.com |
Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation: general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Certain trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries.
Attachment
